## Travere Therapeutics Shares Plunge 33% as FDA Seeks Clarity on Key Kidney Drug Efficacy
Shares of Travere Therapeutics (NASDAQ:TVTX) plummeted by a third on Tuesday after the biotechnology company revealed that the U.S. Food and Drug Administration (FDA) is seeking additional information to clarify the clinical benefit of Filspari, its leading therapy for a rare and severe kidney disorder.
The steep market reaction followed Travere’s disclosure that it recently received several information requests from the FDA aimed at further characterizing the efficacy of Filspari in treating focal segmental glomerulosclerosis (FSGS). FSGS is a chronic condition that damages the filtering units of the kidney and often leads to end-stage renal disease.
While Travere has responded promptly by submitting the data necessary to address the agency’s queries, the timing of these submissions has introduced significant doubt regarding the drug’s imminent regulatory status. The action date under the Prescription Drug User Fee Act (PDUFA) for the supplemental new drug application coincided with the heightened regulatory review, creating immediate uncertainty.
This regulatory hurdle prompted swift analysis from Wall Street, with experts outlining several divergent possibilities. Outcomes range from a simple delay, allowing the FDA time to review the newly furnished data, to the issuance of a Complete Response Letter (CRL), which would require the company to conduct extensive additional efficacy studies.
Evercore ISI analyst Gavin Clark-Gartner observed that prior to the drop, the stock, trading around $22, was already pricing in relatively low odds of immediate approval—estimated at roughly 33%. Clark-Gartner quantified the high-stakes risk-reward dynamic, suggesting that a CRL requiring more studies could send the stock spiraling down to approximately $12 per share, whereas an outright approval could see shares soar toward $43.
Meanwhile, Stifel maintained its Hold rating on Travere, echoing skepticism regarding the likelihood of approval for Filspari in the FSGS indication, especially given concerns stemming from a prior, unsuccessful study. While the firm noted that regulatory delays have become increasingly common, Stifel analysts warned that the prospect of a Complete Response Letter is a palpable threat that could drive the stock valuation into the "low-teens."
Despite the considerable regulatory setback concerning the FSGS indication, Travere provided positive commercial news regarding Filspari’s performance in its already-approved indication for IgA nephropathy (IgAN). The company reported solid fourth-quarter results for the IgAN market, with the number of new patient adds climbing robustly from 731 in the preceding quarter to 908, demonstrating strong underlying commercial momentum where the drug has authorization.
